These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 36109550)

  • 1. Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies.
    Cao X; Maruyama J; Zhou H; Fu Y; Kerwin L; Powers C; Sattler RA; Manning JT; Singh A; Lim R; Healy LD; Johnson S; Paz Cabral E; Li D; Lu L; Ledesma A; Lee D; Richards S; Rivero-Nava L; Li Y; Shen W; Stegman K; Blair B; Urata S; Kishimoto-Urata M; Ko J; Du N; Morais K; Lawrence K; Rivera I; Pai CI; Bresson D; Brunswick M; Zhang Y; Ji H; Paessler S; Allen RD
    Sci Rep; 2022 Sep; 12(1):15517. PubMed ID: 36109550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern
    Chiem K; Morales Vasquez D; Silvas JA; Park JG; Piepenbrink MS; Sourimant J; Lin MJ; Greninger AL; Plemper RK; Torrelles JB; Walter MR; de la Torre JC; Kobie JK; Ye C; Martinez-Sobrido L
    J Virol; 2021 Oct; 95(22):e0112621. PubMed ID: 34495697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of therapeutic antibody efficacy against multiple SARS-CoV-2 variants in the hamster model.
    Cong Y; Dixit S; Perry DL; Huzella LM; Kollins E; Byrum R; Anthony SM; Drawbaugh D; Lembirik S; Postnikova E; Eaton B; Murphy M; Kocher G; Hadley K; Marketon AE; Bernbaum RM; Hischak AMW; Hart R; Vaughan N; Wada J; Qin J; St Claire MC; Schmaljohn CS; Holbrook MR
    Antiviral Res; 2024 Oct; 230():105987. PubMed ID: 39147143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.
    Su W; Sia SF; Schmitz AJ; Bricker TL; Starr TN; Greaney AJ; Turner JS; Mohammed BM; Liu Z; Choy KT; Darling TL; Joshi A; Cheng KM; Wong AYL; Harastani HH; Nicholls JM; Whelan SPJ; Bloom JD; Yen HL; Ellebedy AH; Boon ACM
    mBio; 2021 Oct; 12(5):e0239521. PubMed ID: 34517754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2.
    Xie J; Ding C; He J; Zhang Y; Ni S; Zhang X; Chen Q; Wang J; Huang L; He H; Li W; Ma H; Jin T; Zhang S; Gao Y
    Front Immunol; 2021; 12():715464. PubMed ID: 34539645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies.
    Zhou D; Chan JF; Zhou B; Zhou R; Li S; Shan S; Liu L; Zhang AJ; Chen SJ; Chan CC; Xu H; Poon VK; Yuan S; Li C; Chik KK; Chan CC; Cao J; Chan CY; Kwan KY; Du Z; Lau TT; Zhang Q; Zhou J; To KK; Zhang L; Ho DD; Yuen KY; Chen Z
    Cell Host Microbe; 2021 Apr; 29(4):551-563.e5. PubMed ID: 33657424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19.
    Zumbrun EE; Kaku CI; Dillinger L; Zak SE; Kuehne AI; Bakken RR; Koehler JW; Delp KL; Stefan CP; Kumar R; Kugelman JR; Moreau AM; Zeng X; Dye JM; Herbert AS; Narayan K; Walker LM
    Antimicrob Agents Chemother; 2023 Jan; 67(1):e0135322. PubMed ID: 36519929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics.
    Zhao S; Zhang H; Yang X; Zhang H; Chen Y; Zhan Y; Zhang X; Jiang R; Liu M; Liu L; Chen L; Tang W; Peng C; Gao X; Zhang Z; Shi Z; Gong R
    Nat Commun; 2021 Aug; 12(1):4887. PubMed ID: 34373446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern.
    Chang MR; Tomasovic L; Kuzmina NA; Ronk AJ; Byrne PO; Johnson R; Storm N; Olmedillas E; Hou YJ; Schäfer A; Leist SR; Tse LV; Ke H; Coherd C; Nguyen K; Kamkaew M; Honko A; Zhu Q; Alter G; Saphire EO; McLellan JS; Griffiths A; Baric RS; Bukreyev A; Marasco WA
    Nat Commun; 2022 Oct; 13(1):5814. PubMed ID: 36192374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19.
    Esparza TJ; Chen Y; Martin NP; Bielefeldt-Ohmann H; Bowen RA; Tolbert WD; Pazgier M; Brody DL
    MAbs; 2022; 14(1):2047144. PubMed ID: 35289719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-Throughput Neutralization and Serology Assays Reveal Correlated but Highly Variable Humoral Immune Responses in a Large Population of Individuals Infected with SARS-CoV-2 in the US between March and August 2020.
    Zhang S; Ma P; Orzechowski M; Lemmer A; Rzasa K; Bagnall J; Barkho S; Chen M; He L; Neitupski R; Tran V; Ackerman R; Gath E; Bond A; Frongillo G; Cleland T; Golas A; Gaca A; Fitzgerald M; Kelly K; Hazegh K; Dumont L; Hoffman C; Homer M; Marks P; Woolley A; Wong S; Gomez J; Livny J; Hung D
    mBio; 2023 Apr; 14(2):e0352322. PubMed ID: 36786604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
    Liu L; Wang P; Nair MS; Yu J; Rapp M; Wang Q; Luo Y; Chan JF; Sahi V; Figueroa A; Guo XV; Cerutti G; Bimela J; Gorman J; Zhou T; Chen Z; Yuen KY; Kwong PD; Sodroski JG; Yin MT; Sheng Z; Huang Y; Shapiro L; Ho DD
    Nature; 2020 Aug; 584(7821):450-456. PubMed ID: 32698192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters.
    Roberts A; Thomas WD; Guarner J; Lamirande EW; Babcock GJ; Greenough TC; Vogel L; Hayes N; Sullivan JL; Zaki S; Subbarao K; Ambrosino DM
    J Infect Dis; 2006 Mar; 193(5):685-92. PubMed ID: 16453264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic equine hyperimmune antibodies with high and broad-spectrum neutralizing activity protect rodents against SARS-CoV-2 infection.
    Li E; Han Q; Bi J; Wei S; Wang S; Zhang Y; Liu J; Feng N; Wang T; Wu J; Yang S; Zhao Y; Liu B; Yan F; Xia X
    Front Immunol; 2023; 14():1066730. PubMed ID: 36875106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster.
    Brustolin M; Rodon J; Rodríguez de la Concepción ML; Ávila-Nieto C; Cantero G; Pérez M; Te N; Noguera-Julián M; Guallar V; Valencia A; Roca N; Izquierdo-Useros N; Blanco J; Clotet B; Bensaid A; Carrillo J; Vergara-Alert J; Segalés J
    Emerg Microbes Infect; 2021 Dec; 10(1):797-809. PubMed ID: 33825619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model.
    O'Donnell KL; Pinski AN; Clancy CS; Gourdine T; Shifflett K; Fletcher P; Messaoudi I; Marzi A
    EBioMedicine; 2021 Nov; 73():103675. PubMed ID: 34758415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.
    Jiang S; Hillyer C; Du L
    Trends Immunol; 2020 May; 41(5):355-359. PubMed ID: 32249063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron.
    Wang S; Sun H; Zhang Y; Yuan L; Wang Y; Zhang T; Wang S; Zhang J; Yu H; Xiong H; Tang Z; Liu L; Huang Y; Chen X; Li T; Ying D; Liu C; Chen Z; Yuan Q; Zhang J; Cheng T; Li S; Guan Y; Zheng Q; Zheng Z; Xia N
    Cell Rep; 2022 May; 39(8):110862. PubMed ID: 35594869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.